Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Thrombocythaemia Myelofibrosis – Pipeline Review, H2 2016’, provides an overview of the Thrombocythaemia Myelofibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thrombocythaemia Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thrombocythaemia Myelofibrosis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Thrombocythaemia Myelofibrosis

The report reviews pipeline therapeutics for Thrombocythaemia Myelofibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Thrombocythaemia Myelofibrosis therapeutics and enlists all their major and minor projects

The report assesses Thrombocythaemia Myelofibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Thrombocythaemia Myelofibrosis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Thrombocythaemia Myelofibrosis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Thrombocythaemia Myelofibrosis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Celgene Corporation

Gilead Sciences, Inc.

Incyte Corporation

JW Pharmaceutical Corporation

Nippon Shinyaku Co., Ltd.

Novartis AG

Pfizer Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Thrombocythaemia Myelofibrosis Overview 6

Therapeutics Development 7

Pipeline Products for Thrombocythaemia Myelofibrosis - Overview 7

Pipeline Products for Thrombocythaemia Myelofibrosis - Comparative Analysis 8

Thrombocythaemia Myelofibrosis - Therapeutics under Development by Companies 9

Thrombocythaemia Myelofibrosis - Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Thrombocythaemia Myelofibrosis - Products under Development by Companies 12

Thrombocythaemia Myelofibrosis - Companies Involved in Therapeutics Development 13

Celgene Corporation 13

Gilead Sciences, Inc. 14

Incyte Corporation 15

JW Pharmaceutical Corporation 16

Nippon Shinyaku Co., Ltd. 17

Novartis AG 18

Pfizer Inc. 19

Thrombocythaemia Myelofibrosis - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 28

buparlisib hydrochloride - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

CWP-291 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

glasdegib - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

itacitinib adipate - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

momelotinib dihydrochloride - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

NS-018 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

pomalidomide - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Thrombocythaemia Myelofibrosis - Dormant Projects 52

Thrombocythaemia Myelofibrosis - Discontinued Products 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

Number of Products under Development for Thrombocythaemia Myelofibrosis, H2 2016 7

Number of Products under Development for Thrombocythaemia Myelofibrosis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Thrombocythaemia Myelofibrosis – Pipeline by Celgene Corporation, H2 2016 13

Thrombocythaemia Myelofibrosis – Pipeline by Gilead Sciences, Inc., H2 2016 14

Thrombocythaemia Myelofibrosis – Pipeline by Incyte Corporation, H2 2016 15

Thrombocythaemia Myelofibrosis – Pipeline by JW Pharmaceutical Corporation, H2 2016 16

Thrombocythaemia Myelofibrosis – Pipeline by Nippon Shinyaku Co., Ltd., H2 2016 17

Thrombocythaemia Myelofibrosis – Pipeline by Novartis AG, H2 2016 18

Thrombocythaemia Myelofibrosis – Pipeline by Pfizer Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 27

Thrombocythaemia Myelofibrosis – Dormant Projects, H2 2016 52

Thrombocythaemia Myelofibrosis – Discontinued Products, H2 2016 53

List of Figures

List of Figures

Number of Products under Development for Thrombocythaemia Myelofibrosis, H2 2016 7

Number of Products under Development for Thrombocythaemia Myelofibrosis – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports